CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Lantheus Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Lantheus Holdings Inc
331 Treble Cove Rd
Phone: (978) 671-8001p:978 671-8001 NORTH BILLERICA, MA  01862  United States Ticker: LNTHLNTH
This is a Subsidiary, click here for the Parent Company
Business Summary
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its pipeline also includes breast and other cancers. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, Ga-DOTA-RM2, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
3845 Electromedical and electrotherapeutic apparatus
3844 X-ray apparatus and tubes and related irradiation apparatus
2835 In vitro and in vivo diagnostic substances
7372 Prepackaged software

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Mary A.Heino 64 3/1/2024 4/1/2013
President Paul M.Blanchfield 43 3/20/2023 1/27/2020
Chief Executive Officer, Director Brian A.Markison 64 3/1/2024 9/1/2012
12 additional Officers and Directors records available in full report.

Business Names
Business Name
Cerveau Technologies, Inc.
Cerveau Technologies,Inc.
Excelsior Life Sciences Ireland Limited
16 additional Business Names available in full report.

General Information
Number of Employees: 834 (As of 12/31/2023)
Outstanding Shares: 69,526,841 (As of 10/30/2024)
Shareholders: 30
Stock Exchange: NASD
Federal Tax Id: 352318913
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, November 22, 2024